ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global GLP-1-based Therapy Market Research Report 2026
Published Date: 2026-03-11
|
Report Code: QYRE-Auto-29S17635
Home | Market Reports | Health| Health Conditions
Global GLP 1 based Therapy Market Research Report 2024
BUY CHAPTERS

Global GLP-1-based Therapy Market Research Report 2026

Code: QYRE-Auto-29S17635
Report
2026-03-11
Pages:112
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
Eli Lilly
Astrazeneca plc
Sanofi
GSK
Hanson
Shanghai Renhui Biopharmaceutical
Huadong Medicine
Sino Biopharm

GLP-1-based Therapy Market

The global GLP-1-based Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on GLP-1-based Therapy competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
GLP-1-based therapy involves the use of medications that mimic the actions of glucagon-like peptide-1(GLP-1).They work by stimulating insulin secretion in response to elevated blood sugar levels,inhibiting glucagon release,delaying gastric emptying,and promoting a feeling of fullness.These effects help to lower blood glucose levels,improve glycemic control,and often result in weight loss,which are primarily used to manage type 2 diabetes mellitus and loss weight.
The North American market for GLP-1-based Therapy is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for GLP-1-based Therapy is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of GLP-1-based Therapy include Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Renhui Biopharmaceutical, Huadong Medicine, Sino Biopharm, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global GLP-1-based Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding GLP-1-based Therapy. The GLP-1-based Therapy market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global GLP-1-based Therapy market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist GLP-1-based Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of GLP-1-based Therapy Market Report

Report Metric Details
Report Name GLP-1-based Therapy Market
Segment by Type
  • Injection
  • Tablets
  • Other
by Application
  • Type 2 Diabetes
  • Obesity
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Renhui Biopharmaceutical, Huadong Medicine, Sino Biopharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for GLP-1-based Therapy manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines GLP-1-based Therapy sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the GLP-1-based Therapy Market report?

Ans: The main players in the GLP-1-based Therapy Market are Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Renhui Biopharmaceutical, Huadong Medicine, Sino Biopharm

What are the Application segmentation covered in the GLP-1-based Therapy Market report?

Ans: The Applications covered in the GLP-1-based Therapy Market report are Type 2 Diabetes, Obesity

What are the Type segmentation covered in the GLP-1-based Therapy Market report?

Ans: The Types covered in the GLP-1-based Therapy Market report are Injection, Tablets, Other

1 GLP-1-based Therapy Market Overview
1.1 Product Definition
1.2 GLP-1-based Therapy by Type
1.2.1 Global GLP-1-based Therapy Market Value by Type: 2025 vs 2032
1.2.2 Injection
1.2.3 Tablets
1.2.4 Other
1.3 GLP-1-based Therapy by Application
1.3.1 Global GLP-1-based Therapy Market Value by Application: 2025 vs 2032
1.3.2 Type 2 Diabetes
1.3.3 Obesity
1.4 Global GLP-1-based Therapy Market Size Estimates and Forecasts
1.4.1 Global GLP-1-based Therapy Revenue 2021–2032
1.4.2 Global GLP-1-based Therapy Sales 2021–2032
1.4.3 Global GLP-1-based Therapy Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 GLP-1-based Therapy Market Competition by Manufacturers
2.1 Global GLP-1-based Therapy Sales Market Share by Manufacturers (2021–2026)
2.2 Global GLP-1-based Therapy Revenue Market Share by Manufacturers (2021–2026)
2.3 Global GLP-1-based Therapy Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of GLP-1-based Therapy, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of GLP-1-based Therapy, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of GLP-1-based Therapy, Product Types and Applications
2.7 Global Key Manufacturers of GLP-1-based Therapy, Date of Entry into the Industry
2.8 Global GLP-1-based Therapy Market Competitive Situation and Trends
2.8.1 Global GLP-1-based Therapy Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global GLP-1-based Therapy Players Market Share by Revenue
2.8.3 Global GLP-1-based Therapy Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GLP-1-based Therapy Market Scenario by Region
3.1 Global GLP-1-based Therapy Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global GLP-1-based Therapy Sales by Region: 2021–2032
3.2.1 Global GLP-1-based Therapy Sales by Region: 2021–2026
3.2.2 Global GLP-1-based Therapy Sales by Region: 2027–2032
3.3 Global GLP-1-based Therapy Revenue by Region: 2021–2032
3.3.1 Global GLP-1-based Therapy Revenue by Region: 2021–2026
3.3.2 Global GLP-1-based Therapy Revenue by Region: 2027–2032
3.4 North America GLP-1-based Therapy Market Facts & Figures by Country
3.4.1 North America GLP-1-based Therapy Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America GLP-1-based Therapy Sales by Country (2021–2032)
3.4.3 North America GLP-1-based Therapy Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1-based Therapy Market Facts & Figures by Country
3.5.1 Europe GLP-1-based Therapy Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe GLP-1-based Therapy Sales by Country (2021–2032)
3.5.3 Europe GLP-1-based Therapy Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1-based Therapy Market Facts & Figures by Region
3.6.1 Asia Pacific GLP-1-based Therapy Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific GLP-1-based Therapy Sales by Region (2021–2032)
3.6.3 Asia Pacific GLP-1-based Therapy Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1-based Therapy Market Facts & Figures by Country
3.7.1 Latin America GLP-1-based Therapy Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America GLP-1-based Therapy Sales by Country (2021–2032)
3.7.3 Latin America GLP-1-based Therapy Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1-based Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1-based Therapy Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa GLP-1-based Therapy Sales by Country (2021–2032)
3.8.3 Middle East and Africa GLP-1-based Therapy Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1-based Therapy Sales by Type (2021–2032)
4.1.1 Global GLP-1-based Therapy Sales by Type (2021–2026)
4.1.2 Global GLP-1-based Therapy Sales by Type (2027–2032)
4.1.3 Global GLP-1-based Therapy Sales Market Share by Type (2021–2032)
4.2 Global GLP-1-based Therapy Revenue by Type (2021–2032)
4.2.1 Global GLP-1-based Therapy Revenue by Type (2021–2026)
4.2.2 Global GLP-1-based Therapy Revenue by Type (2027–2032)
4.2.3 Global GLP-1-based Therapy Revenue Market Share by Type (2021–2032)
4.3 Global GLP-1-based Therapy Price by Type (2021–2032)
5 Segment by Application
5.1 Global GLP-1-based Therapy Sales by Application (2021–2032)
5.1.1 Global GLP-1-based Therapy Sales by Application (2021–2026)
5.1.2 Global GLP-1-based Therapy Sales by Application (2027–2032)
5.1.3 Global GLP-1-based Therapy Sales Market Share by Application (2021–2032)
5.2 Global GLP-1-based Therapy Revenue by Application (2021–2032)
5.2.1 Global GLP-1-based Therapy Revenue by Application (2021–2026)
5.2.2 Global GLP-1-based Therapy Revenue by Application (2027–2032)
5.2.3 Global GLP-1-based Therapy Revenue Market Share by Application (2021–2032)
5.3 Global GLP-1-based Therapy Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novo Nordisk GLP-1-based Therapy Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Eli Lilly GLP-1-based Therapy Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 AstraZeneca GLP-1-based Therapy Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Company Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sanofi GLP-1-based Therapy Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 GSK
6.5.1 GSK Company Information
6.5.2 GSK Description and Business Overview
6.5.3 GSK GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 GSK GLP-1-based Therapy Product Portfolio
6.5.5 GSK Recent Developments/Updates
6.6 Hanson
6.6.1 Hanson Company Information
6.6.2 Hanson Description and Business Overview
6.6.3 Hanson GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Hanson GLP-1-based Therapy Product Portfolio
6.6.5 Hanson Recent Developments/Updates
6.7 Shanghai Renhui Biopharmaceutical
6.7.1 Shanghai Renhui Biopharmaceutical Company Information
6.7.2 Shanghai Renhui Biopharmaceutical Description and Business Overview
6.7.3 Shanghai Renhui Biopharmaceutical GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Shanghai Renhui Biopharmaceutical GLP-1-based Therapy Product Portfolio
6.7.5 Shanghai Renhui Biopharmaceutical Recent Developments/Updates
6.8 Huadong Medicine
6.8.1 Huadong Medicine Company Information
6.8.2 Huadong Medicine Description and Business Overview
6.8.3 Huadong Medicine GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Huadong Medicine GLP-1-based Therapy Product Portfolio
6.8.5 Huadong Medicine Recent Developments/Updates
6.9 Sino Biopharm
6.9.1 Sino Biopharm Company Information
6.9.2 Sino Biopharm Description and Business Overview
6.9.3 Sino Biopharm GLP-1-based Therapy Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sino Biopharm GLP-1-based Therapy Product Portfolio
6.9.5 Sino Biopharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1-based Therapy Industry Chain Analysis
7.2 GLP-1-based Therapy Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1-based Therapy Production Mode & Process Analysis
7.4 GLP-1-based Therapy Sales and Marketing
7.4.1 GLP-1-based Therapy Sales Channels
7.4.2 GLP-1-based Therapy Distributors
7.5 GLP-1-based Therapy Customer Analysis
8 GLP-1-based Therapy Market Dynamics
8.1 GLP-1-based Therapy Industry Trends
8.2 GLP-1-based Therapy Market Drivers
8.3 GLP-1-based Therapy Market Challenges
8.4 GLP-1-based Therapy Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novo Nordisk
Eli Lilly
Astrazeneca plc
Sanofi
GSK
Hanson
Shanghai Renhui Biopharmaceutical
Huadong Medicine
Sino Biopharm
List of Tables
 Table 1. Global GLP-1-based Therapy Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global GLP-1-based Therapy Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global GLP-1-based Therapy Market Competitive Situation by Manufacturers in 2025
 Table 4. Global GLP-1-based Therapy Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global GLP-1-based Therapy Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global GLP-1-based Therapy Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global GLP-1-based Therapy Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market GLP-1-based Therapy Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of GLP-1-based Therapy, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of GLP-1-based Therapy, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of GLP-1-based Therapy, Product Types and Applications
 Table 12. Global Key Manufacturers of GLP-1-based Therapy, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global GLP-1-based Therapy Companies by Tier (Tier 1, Tier 2, Tier 3), based on GLP-1-based Therapy Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global GLP-1-based Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global GLP-1-based Therapy Sales by Region (K Units), 2021–2026
 Table 18. Global GLP-1-based Therapy Sales Market Share by Region (2021–2026)
 Table 19. Global GLP-1-based Therapy Sales by Region (K Units), 2027–2032
 Table 20. Global GLP-1-based Therapy Sales Market Share by Region (2027–2032)
 Table 21. Global GLP-1-based Therapy Revenue by Region (US$ Million), 2021–2026
 Table 22. Global GLP-1-based Therapy Revenue Market Share by Region (2021–2026)
 Table 23. Global GLP-1-based Therapy Revenue by Region (US$ Million), 2027–2032
 Table 24. Global GLP-1-based Therapy Revenue Market Share by Region (2027–2032)
 Table 25. North America GLP-1-based Therapy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America GLP-1-based Therapy Sales by Country (K Units), 2021–2026
 Table 27. North America GLP-1-based Therapy Sales by Country (K Units), 2027–2032
 Table 28. North America GLP-1-based Therapy Revenue by Country (US$ Million), 2021–2026
 Table 29. North America GLP-1-based Therapy Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe GLP-1-based Therapy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe GLP-1-based Therapy Sales by Country (K Units), 2021–2026
 Table 32. Europe GLP-1-based Therapy Sales by Country (K Units), 2027–2032
 Table 33. Europe GLP-1-based Therapy Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe GLP-1-based Therapy Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific GLP-1-based Therapy Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific GLP-1-based Therapy Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific GLP-1-based Therapy Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific GLP-1-based Therapy Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific GLP-1-based Therapy Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America GLP-1-based Therapy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America GLP-1-based Therapy Sales by Country (K Units), 2021–2026
 Table 42. Latin America GLP-1-based Therapy Sales by Country (K Units), 2027–2032
 Table 43. Latin America GLP-1-based Therapy Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America GLP-1-based Therapy Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa GLP-1-based Therapy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa GLP-1-based Therapy Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa GLP-1-based Therapy Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa GLP-1-based Therapy Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa GLP-1-based Therapy Revenue by Country (US$ Million), 2027–2032
 Table 50. Global GLP-1-based Therapy Sales (K Units) by Type (2021–2026)
 Table 51. Global GLP-1-based Therapy Sales (K Units) by Type (2027–2032)
 Table 52. Global GLP-1-based Therapy Sales Market Share by Type (2021–2026)
 Table 53. Global GLP-1-based Therapy Sales Market Share by Type (2027–2032)
 Table 54. Global GLP-1-based Therapy Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global GLP-1-based Therapy Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global GLP-1-based Therapy Revenue Market Share by Type (2021–2026)
 Table 57. Global GLP-1-based Therapy Revenue Market Share by Type (2027–2032)
 Table 58. Global GLP-1-based Therapy Price (US$/Unit) by Type (2021–2026)
 Table 59. Global GLP-1-based Therapy Price (US$/Unit) by Type (2027–2032)
 Table 60. Global GLP-1-based Therapy Sales (K Units) by Application (2021–2026)
 Table 61. Global GLP-1-based Therapy Sales (K Units) by Application (2027–2032)
 Table 62. Global GLP-1-based Therapy Sales Market Share by Application (2021–2026)
 Table 63. Global GLP-1-based Therapy Sales Market Share by Application (2027–2032)
 Table 64. Global GLP-1-based Therapy Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global GLP-1-based Therapy Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global GLP-1-based Therapy Revenue Market Share by Application (2021–2026)
 Table 67. Global GLP-1-based Therapy Revenue Market Share by Application (2027–2032)
 Table 68. Global GLP-1-based Therapy Price (US$/Unit) by Application (2021–2026)
 Table 69. Global GLP-1-based Therapy Price (US$/Unit) by Application (2027–2032)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Novo Nordisk GLP-1-based Therapy Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. Eli Lilly Company Information
 Table 76. Eli Lilly Description and Business Overview
 Table 77. Eli Lilly GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Eli Lilly GLP-1-based Therapy Product
 Table 79. Eli Lilly Recent Developments/Updates
 Table 80. AstraZeneca Company Information
 Table 81. AstraZeneca Description and Business Overview
 Table 82. AstraZeneca GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. AstraZeneca GLP-1-based Therapy Product
 Table 84. AstraZeneca Recent Developments/Updates
 Table 85. Sanofi Company Information
 Table 86. Sanofi Description and Business Overview
 Table 87. Sanofi GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Sanofi GLP-1-based Therapy Product
 Table 89. Sanofi Recent Developments/Updates
 Table 90. GSK Company Information
 Table 91. GSK Description and Business Overview
 Table 92. GSK GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. GSK GLP-1-based Therapy Product
 Table 94. GSK Recent Developments/Updates
 Table 95. Hanson Company Information
 Table 96. Hanson Description and Business Overview
 Table 97. Hanson GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Hanson GLP-1-based Therapy Product
 Table 99. Hanson Recent Developments/Updates
 Table 100. Shanghai Renhui Biopharmaceutical Company Information
 Table 101. Shanghai Renhui Biopharmaceutical Description and Business Overview
 Table 102. Shanghai Renhui Biopharmaceutical GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Shanghai Renhui Biopharmaceutical GLP-1-based Therapy Product
 Table 104. Shanghai Renhui Biopharmaceutical Recent Developments/Updates
 Table 105. Huadong Medicine Company Information
 Table 106. Huadong Medicine Description and Business Overview
 Table 107. Huadong Medicine GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Huadong Medicine GLP-1-based Therapy Product
 Table 109. Huadong Medicine Recent Developments/Updates
 Table 110. Sino Biopharm Company Information
 Table 111. Sino Biopharm Description and Business Overview
 Table 112. Sino Biopharm GLP-1-based Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Sino Biopharm GLP-1-based Therapy Product
 Table 114. Sino Biopharm Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. GLP-1-based Therapy Distributors List
 Table 118. GLP-1-based Therapy Customers List
 Table 119. GLP-1-based Therapy Market Trends
 Table 120. GLP-1-based Therapy Market Drivers
 Table 121. GLP-1-based Therapy Market Challenges
 Table 122. GLP-1-based Therapy Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of GLP-1-based Therapy
 Figure 2. Global GLP-1-based Therapy Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global GLP-1-based Therapy Market Share by Type: 2025 & 2032
 Figure 4. Injection Product Picture
 Figure 5. Tablets Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global GLP-1-based Therapy Market Value by Application (US$ Million), 2021–2032
 Figure 8. Global GLP-1-based Therapy Market Share by Application: 2025 & 2032
 Figure 9. Type 2 Diabetes
 Figure 10. Obesity
 Figure 11. Global GLP-1-based Therapy Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global GLP-1-based Therapy Market Size (US$ Million), 2021–2032
 Figure 13. Global GLP-1-based Therapy Sales (K Units), 2021–2032
 Figure 14. Global GLP-1-based Therapy Average Price (US$/Unit), 2021–2032
 Figure 15. GLP-1-based Therapy Report Years Considered
 Figure 16. GLP-1-based Therapy Sales Share by Manufacturers in 2025
 Figure 17. Global GLP-1-based Therapy Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global GLP-1-based Therapy Players: Market Share by Revenue in GLP-1-based Therapy in 2025
 Figure 19. GLP-1-based Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global GLP-1-based Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America GLP-1-based Therapy Sales Market Share by Country (2021–2032)
 Figure 22. North America GLP-1-based Therapy Revenue Market Share by Country (2021–2032)
 Figure 23. United States GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe GLP-1-based Therapy Sales Market Share by Country (2021–2032)
 Figure 26. Europe GLP-1-based Therapy Revenue Market Share by Country (2021–2032)
 Figure 27. Germany GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific GLP-1-based Therapy Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific GLP-1-based Therapy Revenue Market Share by Region (2021–2032)
 Figure 34. China GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America GLP-1-based Therapy Sales Market Share by Country (2021–2032)
 Figure 42. Latin America GLP-1-based Therapy Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa GLP-1-based Therapy Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa GLP-1-based Therapy Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE GLP-1-based Therapy Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of GLP-1-based Therapy by Type (2021–2032)
 Figure 53. Global Revenue Market Share of GLP-1-based Therapy by Type (2021–2032)
 Figure 54. Global GLP-1-based Therapy Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of GLP-1-based Therapy by Application (2021–2032)
 Figure 56. Global Revenue Market Share of GLP-1-based Therapy by Application (2021–2032)
 Figure 57. Global GLP-1-based Therapy Price (US$/Unit) by Application (2021–2032)
 Figure 58. GLP-1-based Therapy Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Weight Loss Drug Market Research Report 2024
GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Injection Market Research Report 2024
Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025
Global GLP 1 Agonists for Obesity Market Research Report 2024
Global Oral GLP 1 Agonist Market Research Report 2024
Global GLP 1 Drug Peptide API Market Research Report 2024
Global GLP 1 Receptor Agonist Drugs Market Research Report 2024
Global GLP 1 Weight Loss Injection Market Research Report 2024
Global GLP 1 Weight Loss Pill Market Research Report 2024
Global GLP 1 Agonist Injection Market Research Report 2024
Global GLP 1 Drugs Market Research Report 2024
Global GLP 1RA based Therapy for Obesity Market Research Report 2024
GLP 1 for Diabetes Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1RA Therapy Market Research Report 2024
Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025
Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025
Global GLP 1 Receptor Antagonist Market Research Report 2024
Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions